Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Publisher Pubmed



Farajollahimoghadam M1 ; Sanjarimoghaddam H1 ; Ghazizadeh Hasemi M2 ; Sanatian Z1 ; Talaei A3 ; Akhondzadeh S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Psychiatric Research Center, Roozbeh Hospital, Tehran University Of Medical Sciences, Iran
  2. 2. Mental Health Research Center, Iran University Of Medical Sciences, Iran
  3. 3. Psychiatry And Behavioral Sciences Research Center, Department Of Psychiatry, School Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran

Source: International Clinical Psychopharmacology Published:2021


Abstract

In this randomized, double-blind, placebo-controlled clinical trial, we assessed the efficacy and safety of pentoxifylline combination therapy with sertraline in treatment of major depressive disorder (MDD). A total of 56 patients with MDD were assigned into two parallel groups to receive sertraline (100 mg/day) plus placebo or sertraline (100 mg/day) plus pentoxifylline (400 mg three times daily) for six weeks. Patients were evaluated with the Hamilton rating scale for depression (HAM-D) at baseline and weeks 2, 4 and 6. The sertraline plus pentoxifylline group demonstrated greater improvement in HAM-D scores from baseline to all three study time points (P = 0.013, 0.007 and 0.016 for week 2, 4 and 6, respectively). Response to treatment rate was also significantly higher in the sertraline plus pentoxifylline group compared to the sertraline plus placebo group at week 4 [57.1 vs. 21.4%, P = 0.013] and the study endpoint [96.4 vs. 57.1%, P = 0.001]. However, the remission rate, time to remission and time to treatment response did not show any significant difference between trial groups. Our findings support the efficacy and safety of pentoxifylline combination therapy in patients with MDD. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Related Docs
View other Related Docs
1. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
2. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)
3. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)
4. Pentoxifylline for Treatment of Major Depression After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2021)
5. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
6. Evidence for Anti-Inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial, Clinical Neuropharmacology (2022)
7. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Annals of Pharmacotherapy (2015)
8. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (33)
Ahmad Ali Noorbala Tafti (5)
Other Related Docs
9. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)
10. Celecoxib Adjunctive Therapy for Acute Bipolar Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Bipolar Disorders (2015)
11. Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)
12. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
13. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)
14. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)
15. Efficacy and Safety of Celecoxib for Treatment of Mild to Moderate Postpartum Depression: A Randomized, Double-Blind, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2024)
16. Evidence for Additionally Increased Apoptosis in the Peripheral Blood Mononuclear Cells of Major Depressive Patients With a High Risk for Suicide, American Journal of Medical Genetics# Part B: Neuropsychiatric Genetics (2018)
17. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
18. Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
19. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents With Acute Bipolar Mania, Journal of Child and Adolescent Psychopharmacology (2017)
20. The Effects of Pioglitazone Adjuvant Therapy on Negative Symptoms of Patients With Chronic Schizophrenia: A Double-Blind and Placebo-Controlled Trial, Human Psychopharmacology (2016)
21. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)
22. Evaluation of Inflammatory Markers in Patients With Depressed Episodes in Major Depressive Disorder and Bipolar Disorder Before and After Treatment, Iranian Journal of Allergy# Asthma and Immunology (2023)
23. Palmitoylethanolamide As Adjunctive Therapy for Autism: Efficacy and Safety Results From a Randomized Controlled Trial, Journal of Psychiatric Research (2018)
24. Efficacy of Gemfibrozil As an Adjunct to Sertraline in Major Depressive Disorder, a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2021)
25. Effect of Prebiotic and Probiotic Supplementation on Circulating Pro-Inflammatory Cytokines and Urinary Cortisol Levels in Patients With Major Depressive Disorder: A Double-Blind, Placebo-Controlled Randomized Clinical Trial, Journal of Functional Foods (2019)
26. Celecoxib As an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial, Pharmacopsychiatry (2015)
27. Effect of Adjunctive Celecoxib on Bdnf in Manic Patients Undergoing Electroconvulsive Therapy: A Randomized Double Blind Controlled Trial, Pharmacopsychiatry (2015)
28. Basic Science and Clinical Studies on Non-Covid-19 Topics, of Coronavirus Victims, Avicenna Journal of Medical Biotechnology (2020)
29. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)
30. L-Carnosine As Adjunctive Therapy in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)
31. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
32. L-Carnosine As an Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Psychiatry Research (2018)
33. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
34. Efficacy and Safety of Celecoxib Monotherapy for Treatment of Moderate Depressive Symptoms Following Covid-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2023)
35. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
36. Nlrp3 Inflammatory Pathway. Can We Unlock Depression?, Brain Research (2024)
37. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)